- Oops!Something went wrong.Please try again later.
Shares of Haemonetics (NYSE:HAE) were flat in pre-market trading after the company reported Q3 results.
Earnings per share fell 13.83% year over year to $0.81, which beat the estimate of $0.65.
Revenue of $240,371,000 declined by 7.18% from the same period last year, which beat the estimate of $224,290,000.
Haemonetics hasn't issued any earnings guidance for the time being.
Haemonetics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Feb 02, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/6nszefg7
Company's 52-week high was at $129.92
Company's 52-week low was at $63.41
Price action over last quarter: Up 16.87%
Haemonetics Corp sells products used to process, handle, and analyze blood. The firm sells products in four categories: Plasma, Hemostasis Management, Blood Center and Cell Processing. The Plasma business includes plasma collection devices and disposables. Hemostasis Management includes devices and methodologies for measuring coagulation characteristics of blood, Blood Center includes blood collection and processing devices and disposables for red cells and Cell Processing include surgical blood salvage systems, specialized blood cell processing systems, disposables and blood transfusion management software.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.